-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Docetaxel in Muscle Invasive Bladder Cancer (MIBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Docetaxel in Muscle Invasive Bladder Cancer (MIBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Docetaxel in Muscle Invasive Bladder Cancer (MIBC) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GEN-1047 in Squamous Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GEN-1047 in Squamous Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GEN-1047 in Squamous Non-Small Cell Lung Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olutasidenib in Glioma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Olutasidenib in Glioma Drug Details: Olutasidenib (Rezlidhia) is an isocitrate dehydrogenase-1 (IDH1) inhibitor. It is...
-
Company Profile
Rogers Corp – Company Profile
Rogers Corp (Rogers) is a diversified company. It designs, develops, manufactures and sells engineered materials and components. The company offering products includes elastomer components, RF solutions laminates and 3d printable materials, polyurethane materials, silicone materials, ceramic substrates, circuit materials, busbars, prepregs and bondplys, among others. Rogers's markets its product under the brands 92ML, AD Series, CuClad, Kappa, DiClad, IsoClad, MAGTREX, Radix, RO3000, RO4000, RT/duroid, ROLINX, ENDUR, NITROPHYL and XRD, among others. It serves aerospace and defense, medical, automotive and EV,...
Add to Basket -
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – XRD-0394
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry XRD-0394 Drug Details XRD-0394 is under development for the treatment of metastatic, locally advanced...
-
Product Insights
Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Serine Protein Kinase ATM is a serine/threonine protein kinase. It plays a role in replication-dependent histone mRNA degradation. The Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) Development market research report provides an in-depth analysis of Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted pipeline therapeutics. The report provides comprehensive information on the Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics, complete with analysis by...